2019 American Transplant Congress
Post-Transplant Cancer Following Living Donor HLA-Incompatible Kidney Transplantation
1Johns Hopkins University, Baltimore, MD, 2University of Alabama, Birmingham, AL
*Purpose: Incompatible living donor kidney transplantation (ILDKT) recipients require increased immunosuppression compared to their compatible living donor kidney transplant (CLDKT) counterparts. This continued exposure to…2019 American Transplant Congress
Early Use of Everolimus Plus Reduced Tacrolimus vs Standard Tacrolimus in De Novo Livertransplant Recipients: 12 Months Efficacy and Safety Data from HEPHAISTOS Study
1Study Group, Hephaistos, Germany, 2Novartis Pharma GmbH, Nuernberg, Germany
*Purpose: The HEPHAISTOS study was set up to compare early use of everolimus [EVR] combined with reduced tacrolimus [rTAC] versus standard-dose tacrolimus [TAC-C) in de…2019 American Transplant Congress
Kidney Xenotransplantation from Genetically Engineered Pigs to Baboons with FDA-Approved Immunosuppressive Therapy
*Purpose: Genetically-engineered pigs might present a solution to the critical shortage of organs for clinical transplantation. The aims of this study were to evaluate the…2019 American Transplant Congress
Improving Medication Adherence and Outcomes in Adult Kidney Transplant Patients Using SystemCHANGETM: Results of the Medication Adherence Given Individual Change (MAGIC) Randomized Clinical Trial
*Purpose: Medication non-adherence is an obdurate problem associated with poor outcomes and staggering costs. Even with multi-faceted interventions, effect sizes reported in meta-analyses of medication…2019 American Transplant Congress
Beta2-Adrenergic Receptor Activation Prolongs Survival of Vascularized Composite Tissue Allotransplants in a Murine Model
*Purpose: Transplantation of faces, hands, and limbs using vascularized composite allotransplantation (VCA) has faced significant challenges hindering its routine implementation in the clinic. One critical…2019 American Transplant Congress
Conversion from Tacrolimus Immediate Release to Tacrolimus Extended Release (Envarsus XR®): A Real World Cohort Highlighting Dosing Variability among Patients
*Purpose: Tacrolimus extended release (TacER) (Envarsus XR®) has become an attractive alternative to tacrolimus immediate release (TacIR) due to its once daily dosing scheme, favorable…2019 American Transplant Congress
Adverse Effect Differences between Tacrolimus-IR and LCP-Tacrolimus
*Purpose: Extended-release tacrolimus (Envarsus XR®, LCP-Tac) was approved in 2015 as conversion from tacrolimus immediate-release (Tac-IR) as part of the maintenance immunosuppression regiment post-kidney transplant.…2019 American Transplant Congress
Costs Associated with A2 to B Kidney Transplantation: A Barrier to Its Utilization?
Vanderbilt University Medical Center, Nashville, TN
*Purpose: In 2014 the updated Kidney Allocation System (KAS) allowed for allocation of blood type A2 kidneys to B recipients in an effort to ameliorate…2019 American Transplant Congress
Store-Operated/Calcium Release Activated Calcium Channel Orai3 is a Novel Target for Immunoregulation
1WCMC, New York, NY, 2WCMC, Doha, Qatar
*Purpose: Store-operated/calcium release activated calcium (CRAC) channels are essential for the signaling of immune cells via calcineurin, a calcium-calmodulin dependent serine-threonine phosphatase. The central importance…2019 American Transplant Congress
Cidofovir for BK Nephropathy Rescue Treatment: A Single Center Experience
*Purpose: Cidofovir is a potentially nephrotoxic antiviral drug used primarily as a treatment for CMV retinitis however due to its potent antiviral effects has been…
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 138
- Next Page »